@incollection{,
	
					
					
					A6056B5CDE1711860088B534C77B4118
				,
	author={{AmySun} and {Raymond L.Lam} and {AmyHarman} and {Anna C.Pavlick} and {Gary A.Herman} and {}},
	journal={{Global Journal of Medical Research}},
	journal={{GJMR}}2249-46180975-588810.34257/GJMR,
	address={Cambridge, United States},
	publisher={Global Journals Organisation}1411121
}

@incollection{b0,
	
	
		,
	title={{Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line}}
		,
	author={{
			OHashimoto
		}}
	
	
		,
	journal={{BMC Cancer}}
		
			6
			292
			,
	year={2006}
		
	

}

@incollection{b1,
	
	
		,
	title={{Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents}}
		,
	author={{
			HHirai
		}}
	
	
		,
	journal={{Mol Cancer Ther}}
		
			8
			
			,
	year={2009}
		
	

}

@incollection{b2,
	
	
		,
	title={{MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil}}
		,
	author={{
			HHirai
		}}
	
	
		,
	journal={{Cancer Biol Ther}}
		
			9
			
			,
	year={2010}
		
	

}

@incollection{b3,
	
	
		,
	title={{G2 checkpoint abrogators as anticancer drugs}}
		,
	author={{
			TKawabe
		}}
	
	
		,
	journal={{Mol Cancer Ther}}
		
			3
			
			,
	year={2004}
		
	

}

@incollection{b4,
	
	
		,
	title={{Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNADamaging Agents}}
		,
	author={{
			SLeijen
		} and {
			JHBeijnen
		} and {
			JHSchellens
		}}
		
		
	
	
		,
	journal={{Curr Clin Pharmacol}}
		
			5
			
			,
	year={2010}
		
	

}

@incollection{b5,
	
	
		,
	title={{Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor}}
		,
	author={{
			JLi
		} and {
			YWang
		} and {
			YSun
		} and {
			TSLawrence
		}}
		
		
		
	
	
		,
	journal={{Radiat Res}}
		
			157
			
			,
	year={2002}
		
	

}

@incollection{b6,
	
	
		,
	title={{Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor}}
		,
	author={{
			SMizuarai
		}}
	
	
		,
	journal={{Mol Cancer}}
		
			8
			34
			,
	year={2009}
		
	

}

@incollection{b7,
	
	
		,
	title={{The G2-phase DNA-damage checkpoint}}
		,
	author={{
			MJO'connell
		} and {
			NCWalworth
		} and {
			AMCarr
		}}
		
		
	
	
		,
	journal={{Trends Cell Biol}}
		
			10
			
			,
	year={2000}
		
	

}

@incollection{b8,
	
	
		,
	title={{Toxicity and Response: Criteria of the Eastern Cooperative Oncology Group}}
		,
	author={{
			MOken
		}}
	
	
		,
	journal={{Am J Clin Oncol}}
		
			5
			
			,
	year={1982}
		
	

}

@incollection{b9,
	
	
		,
	title={{How to improve R&D productivity: the pharmaceutical industry's grand challenge}}
		,
	author={{
			SMPaul
		}}
	
	
		,
	journal={{Nat Rev Drug Discov}}
		
			9
			
			,
	year={2010}
		
	

}

@incollection{b10,
	
	
		,
	title={{Gemcitabine: metabolism, mechanisms of action, and selfpotentiation}}
		,
	author={{
			WPlunkett
		} and {
			PHuang
		} and {
			YZXu
		} and {
			VHeinemann
		} and {
			RGrunewald
		} and {
			VGandhi
		}}
		
		
		
		
		
	
	
		,
	journal={{Semin Oncol}}
		
			22
			
			,
	year={1995}
		
	

}

@incollection{b11,
	
	
		,
	title={{Anticancer drug targets: cell cycle and checkpoint control}}
		,
	author={{
			GIShapiro
		} and {
			JWHarper
		}}
		
	
	
		,
	journal={{J Clin Invest}}
		
			104
			
			,
	year={1999}
		
	

}